Developer docs
API playgroundTry for free, no card

Search company profiles

SalioGen Therapeutics

Full company profile

uuid0000px9

Namestring
SalioGen Therapeutics
Legal namestring
SalioGen Therapeutics
Websiteurl
saliogen.com
Company typeenum
Private
Founded yearint
2020
Short descriptiontext

SalioGen Therapeutics was a preclinical genetic medicine company developing a proprietary platform for inherited retinal disorders. The venture-backed biotech raised approximately $135 million before ceasing operations by 2025, without advancing to clinical-stage development.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBurlington, United States
HQ citystring
Burlington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy development, genetic medicines, inherited retinal disorders, preclinical biotechnology, gene coding platform
Industry1 code
PRIMARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
Gene Therapy / Genetic Medicine
Social media profiles2 records
Revenue model1 record
1Pre-revenue
TypeSubscription Recurring
Description

The company was in preclinical research stage and is no longer operating. No commercial revenue was generated.

saliogen.com
Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SalioGen Therapeutics was a preclinical-stage genetic medicine company developing a proprietary gene coding platform intended to produce potentially curative therapies for patients with inherited disorders, with an initial focus on inherited retinal dystrophies. The company ceased operations in 2025 and had not advanced any therapeutic candidates to clinical or commercial stage during its operating history.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Genetic Medicines Platform
CategoryGene Therapy / Genetic Medicine Platform
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Peers10 records
TypeDirect peer
Description

Clinical-stage gene therapy company with multiple inherited retinal disorder programs (e.g., AAV-RPGR for X-linked retinitis pigmentosa) and in-house manufacturing — a direct comparable in both indication and vertical-integration strategy.

TypeDirect peer
Description

Clinical-stage gene therapy developer with lead programs in wet AMD and diabetic retinopathy, competing for the same retinal disorder patient populations and investor mindshare as SalioGen.

TypeDirect peer
Description

Gene-editing company with a clinical-stage program (EDIT-101/reniogene zamparparvovec) in Leber congenital amaurosis 10, directly competing in inherited retinal disorder gene therapy.

TypeDirect peer
Description

AAV gene therapy platform company with clinical-stage retinal programs (e.g., RGX-314) partnered with AbbVie, competing both as a platform licensor and as an IRD therapeutics developer.

TypeDirect peer
Description

Gene therapy company developing therapies for inherited retinal diseases and optic neuropathies (e.g., Lumevoq for LHON), making it a direct peer in the IRD gene therapy category.

TypeBroad incumbent
Description

Pioneer in IRD gene therapy (approved Luxturna/voretigene neparvovec for RPE65-mediated IRDs), now a Roche subsidiary; a broad incumbent that defines the regulatory and commercial benchmark for any IRD gene therapy entrant.

TypeEmerging player
Description

Clinical-stage company engineering novel AAV capsids for targeted gene therapy delivery, with retinal disease programs, making it a platform-level peer in next-generation gene therapy delivery.

TypeEmerging player
Description

Clinical-stage optogenetics and gene therapy company focused on retinal degenerative diseases (e.g., retinitis pigmentosa and Stargardt disease), addressing the same patient populations as SalioGen via a different modality.

TypeEmerging player
Description

RNA-editing company developing Axiomer-based therapies for inherited retinal diseases (e.g., Leber congenital amaurosis and Usher syndrome), an adjacent but modality-adjacent peer in the same indication space.

TypeOthers
Description

Commercial-stage genetic medicines company with a non-viral, redosable platform and approved product (Vyjuvek); comparable as a small genetic-medicine platform that successfully traversed from preclinical to commercial stage, providing a strategic reference point for what SalioGen aspired to build.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SalioGen Therapeutics

Gene Therapy / Genetic Medicinesaliogen.com

SalioGen Therapeutics was a preclinical genetic medicine company developing a proprietary platform for inherited retinal disorders. The venture-backed biotech raised approximately $135 million before ceasing operations by 2025, without advancing to clinical-stage development.

SalioGen Therapeutics firmographics

Firmographics
Name
SalioGen Therapeutics
Legal name
SalioGen Therapeutics
Website
https://saliogen.com
Company type
Private
Founded year
2020
Operating status
Closed
Headcount range
11–50 employees
Short description
SalioGen Therapeutics was a preclinical genetic medicine company developing a proprietary platform for inherited retinal disorders. The venture-backed biotech raised approximately $135 million before ceasing operations by 2025, without advancing to clinical-stage development.
Ownership category
akta.pro rank

SalioGen Therapeutics industry classification

Industry
Product category
Gene Therapy / Genetic Medicine
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Gene therapy development
  • Genetic medicines
  • Inherited retinal disorders
  • Preclinical biotechnology
  • Gene coding platform

Where SalioGen Therapeutics is headquartered

Location

Headquarters

HQ city
Burlington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

SalioGen Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

  1. Pre-revenue: The company was in preclinical research stage and is no longer operating. No commercial revenue was generated.

SalioGen Therapeutics product offering

Product offering

Core offering

SalioGen Therapeutics was a preclinical-stage genetic medicine company developing a proprietary gene coding platform intended to produce potentially curative therapies for patients with inherited disorders, with an initial focus on inherited retinal dystrophies. The company ceased operations in 2025 and had not advanced any therapeutic candidates to clinical or commercial stage during its operating history.

Differentiator

Problem solved

Functional benefit

Products and services

  • Genetic Medicines Platform

Companies that use SalioGen Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

SalioGen Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

SalioGen Therapeutics partnerships and signals

Strategic signal

Scale indicators2 records

SalioGen Therapeutics competitors and assessment

Company assessment

Direct peers

  • MeiraGTx Holdings: Clinical-stage gene therapy company with multiple inherited retinal disorder programs (e.g., AAV-RPGR for X-linked retinitis pigmentosa) and in-house manufacturing — a direct comparable in both indication and vertical-integration strategy.
  • Adverum Biotechnologies: Clinical-stage gene therapy developer with lead programs in wet AMD and diabetic retinopathy, competing for the same retinal disorder patient populations and investor mindshare as SalioGen.
  • Editas Medicine: Gene-editing company with a clinical-stage program (EDIT-101/reniogene zamparparvovec) in Leber congenital amaurosis 10, directly competing in inherited retinal disorder gene therapy.
  • REGENXBIO: AAV gene therapy platform company with clinical-stage retinal programs (e.g., RGX-314) partnered with AbbVie, competing both as a platform licensor and as an IRD therapeutics developer.
  • GenSight Biologics: Gene therapy company developing therapies for inherited retinal diseases and optic neuropathies (e.g., Lumevoq for LHON), making it a direct peer in the IRD gene therapy category.

Broad incumbents

  • Spark Therapeutics (Roche): Pioneer in IRD gene therapy (approved Luxturna/voretigene neparvovec for RPE65-mediated IRDs), now a Roche subsidiary; a broad incumbent that defines the regulatory and commercial benchmark for any IRD gene therapy entrant.

Emerging players

  • 4D Molecular Therapeutics: Clinical-stage company engineering novel AAV capsids for targeted gene therapy delivery, with retinal disease programs, making it a platform-level peer in next-generation gene therapy delivery.
  • Nanoscope Therapeutics: Clinical-stage optogenetics and gene therapy company focused on retinal degenerative diseases (e.g., retinitis pigmentosa and Stargardt disease), addressing the same patient populations as SalioGen via a different modality.
  • ProQR Therapeutics: RNA-editing company developing Axiomer-based therapies for inherited retinal diseases (e.g., Leber congenital amaurosis and Usher syndrome), an adjacent but modality-adjacent peer in the same indication space.

Others

  • Krystal Biotech: Commercial-stage genetic medicines company with a non-viral, redosable platform and approved product (Vyjuvek); comparable as a small genetic-medicine platform that successfully traversed from preclinical to commercial stage, providing a strategic reference point for what SalioGen aspired to build.

Market position

Customer concentration

SalioGen Therapeutics social profiles

Digital presence

SalioGen Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SalioGen Therapeutics leadership team

Management profile

Number of profiles

SalioGen Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SalioGen Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SalioGen Therapeutics

What does SalioGen Therapeutics do?

SalioGen Therapeutics was a preclinical-stage genetic medicine company developing a proprietary gene coding platform intended to produce potentially curative therapies for patients with inherited disorders, with an initial focus on inherited retinal dystrophies. The company ceased operations in 2025 and had not advanced any therapeutic candidates to clinical or commercial stage during its operating history.

Is SalioGen Therapeutics a public or private company?

SalioGen Therapeutics is a private company. It is classified as venture growth investor backed and is currently closed.

When was SalioGen Therapeutics founded?

SalioGen Therapeutics was founded in 2020. It employs 11 to 50 people.

Where is SalioGen Therapeutics based?

SalioGen Therapeutics is headquartered in Burlington, United States, in the North America region.

How does SalioGen Therapeutics make money?

One revenue line is on record: pre-revenue.

Who are SalioGen Therapeutics's main competitors?

Direct peers on record are MeiraGTx Holdings, Adverum Biotechnologies, Editas Medicine, REGENXBIO and GenSight Biologics. Spark Therapeutics (Roche) is listed as a broad incumbent. Emerging players are 4D Molecular Therapeutics, Nanoscope Therapeutics and ProQR Therapeutics. Krystal Biotech is listed as an others.

Does SalioGen Therapeutics have an API?

No public API is recorded for SalioGen Therapeutics.

What industry is SalioGen Therapeutics in?

SalioGen Therapeutics's product category is Gene Therapy / Genetic Medicine. Its primary akta.pro industry code is HLAAACAG, Ophthalmology Gene Therapies. Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comGene Therapy Market Transformation Report 2036: Innovation Trends, Sustainability Drivers & Competitive PositioningThe global gene therapy market is valued at US$ 10.34 billion in 2026 and is projected to reach US$ 38.52 billion by 2036, growing at a 14.1% CAGR, driven by increasing rare disease prevalence and advancements in genome editing. North America is estimated to hold 34.8% of global market share by 2036, while India and the United States are identified as the fastest-growing markets with CAGRs of 22.4% and 13.4% respectively. Key market developments include the FDA's 2023 approvals of Casgevy and Lyfgenia for sickle cell disease, Novartis AG's acquisition of Gyroscope Therapeutics, and the Cystic Fibrosis Foundation's investment in SalioGen Therapeutics, representing significant milestones in the gene therapy landscape.STATSalioGen Therapeutics hit by layoffs, as gene-editing biotechs continue to struggleSalioGen Therapeutics, which raised $135 million for a gene-editing technology, has instituted widespread layoffs and is scaling back its ambitions. The company, launched in 2021, aims to insert full-length genes, a feat older CRISPR-based approaches cannot readily achieve.MorningstarSalioGen Therapeutics Appoints Kali Stasi, M.D., Ph.D. as Chief Medical OfficerSalioGen Therapeutics appointed Kali Stasi, M.D., Ph.D., as Chief Medical Officer. She will lead bringing SGT-1001 to clinic for Stargardt disease by mid-2025 and develop Gene Coding technology for other diseases. Dr. Stasi brings 30 years of ophthalmology and genetic medicine experience.PR NewswireNanite Announces Strategic Collaboration with SalioGen Therapeutics to Develop Non-Viral, Lung-Targeting Nanoparticle for Cystic Fibrosis Genetic MedicineNanite, Inc. and SalioGen Therapeutics announced a research collaboration to develop a non-viral, lung-targeting polymer nanoparticle for cystic fibrosis genetic medicine, combining Nanite's SAYER™ delivery platform with SalioGen's Gene Coding™ technology. In vitro experiments have already demonstrated successful integration of the full-length CFTR gene into human lung cells, with the companies aiming to create what they describe as the first permanent therapy for people with cystic fibrosis regardless of mutation type. The collaboration positions both companies to potentially overcome limitations of existing viral vectors and lipid nanoparticles in gene therapy delivery.PR NewswireSalioGen Therapeutics Announces Data Presentations at 2024 Annual Meetings for the Association for Research in Vision and Ophthalmology (ARVO) and American Society of Gene & Cell Therapy (ASGCT)SalioGen Therapeutics announced that four abstracts, including one oral presentation, will be presented at the upcoming annual meetings of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle and the American Society of Gene & Cell Therapy (ASGCT) in Baltimore in May 2024. The presentations will showcase pre-clinical data supporting SGT-1001, a development candidate for one-time treatment of Stargardt disease, as well as new in vitro data demonstrating site-specific integration of the CFTR gene for cystic fibrosis. The company will also present genomic profiling data on its Gene Coding technology, which uses transposition to integrate large DNA constructs (up to 100kb) into the genome without double-strand breaks or guide RNA.PR NewswireSalioGen Therapeutics Announces Selection of Development Candidate for ABCA4-mediated Stargardt DiseaseSalioGen Therapeutics announced the nomination of SGT-1001 as its first development candidate for Stargardt disease, a rare inherited retinal disease affecting an estimated 30,000 people in the United States with no existing treatments. SGT-1001 is a one-time, non-viral therapy using SalioGen's novel Gene Coding technology that integrates the full-length ABCA4 gene via a proprietary lipid nanoparticle to potentially slow or stop progressive central vision loss. The company plans to complete IND-enabling studies in the second half of 2024 and advance into clinical trials in the first half of 2025.GlobeNewswireSalioGen Therapeutics Appoints Jason F. Cole as Chief Executive Officer and Chairman of the Board of DirectorsSalioGen Therapeutics appointed Jason F. Cole as CEO and Chairman of its Board of Directors. He brings 20 years of biotech experience, including roles at bluebird bio where he led strategic and financial operations. He will lead the company's Gene Coding technology toward the clinic.BioSpaceSalioGen Therapeutics Strengthens its Leadership Team to Advance its Gene Coding™ PlatformSalioGen Therapeutics announced the addition of five executives to its leadership team, including Cathryn Clary as SVP of Clinical Development and Chief Medical Officer. The appointments aim to accelerate R&D, clinical preparations, and operational needs for its Gene Coding platform. The company plans to focus on inherited macular and lipid disorders.GlobeNewswireSalioGen Therapeutics Strengthens its Leadership Team to Advance its Gene Coding™ PlatformSalioGen Therapeutics announced the addition of five executives to its leadership team, including Cathryn Clary as SVP of Clinical Development and Chief Medical Officer. The appointments aim to accelerate R&D, clinical preparations, and operational needs for its Gene Coding platform. The company plans to focus on inherited macular and lipid disorders.